Lepm1Btlr/Lepm1Btlr
C57BL/6J-Lepm1Btlr
|
increased body fat mass |
J:189953
|
|
obese |
J:189953
|
Lepm1Yst/Lepm1Yst
C57BL/6J-Lepm1Yst
|
abnormal eating behavior |
J:167736
|
|
abnormal gonadal fat pad morphology |
J:167736
|
|
decreased body temperature |
J:167736
|
|
hepatic steatosis |
J:167736
|
|
impaired glucose tolerance |
J:167736
|
|
increased body length |
J:167736
|
|
increased body weight |
J:167736
|
|
increased brown adipose tissue amount |
J:167736
|
|
increased brown fat cell lipid droplet size |
J:167736
|
|
increased circulating cholesterol level |
J:167736
|
|
increased circulating glucose level |
J:167736
|
|
increased circulating insulin level |
J:167736
|
|
increased circulating leptin level |
J:167736
|
|
increased circulating triglyceride level |
J:167736
|
|
increased defecation amount |
J:167736
|
|
increased heart weight |
J:167736
|
|
increased inguinal fat pad weight |
J:167736
|
|
increased kidney weight |
J:167736
|
|
increased liver weight |
J:167736
|
|
increased macrophage cell number |
J:167736
|
|
increased total body fat amount |
J:167736
|
|
increased white adipose tissue amount |
J:167736
|
|
increased white fat cell number |
J:167736
|
|
increased white fat cell size |
J:167736
|
|
infertility |
J:167736
|
|
insulin resistance |
J:167736
|
|
obese |
J:167736
|
|
pale liver |
J:167736
|
|
polyuria |
J:167736
|
Lepm2Btlr/Lepm2Btlr
C57BL/6J-Lepm2Btlr
|
obese |
J:234238
|
Lepob/Lep+
involves: 129X1/SvJ * C57BL/6
|
increased liver weight |
J:76479
|
Lepob/Lep+
involves: C57BL/6J
|
increased bone mass |
J:60001
|
Lepob/Lepob-2J
involves: C57BL/6J * SM/Ckc
|
obese |
J:30778
|
Lepob/Lepob
B6.Cg-Lepob/J
|
abnormal body weight |
J:22025,
J:29075
|
|
abnormal bone marrow morphology |
J:189019
|
|
abnormal circulating cholesterol level |
J:18161
|
|
abnormal circulating glucose level |
J:5400
|
|
abnormal epididymal fat pad morphology |
J:22377
|
|
abnormal food intake |
J:122746
|
|
abnormal frequency of paradoxical sleep |
J:115771
|
|
abnormal liver weight |
J:22377
|
|
abnormal muscle morphology |
J:151518
|
|
abnormal myocardial fiber morphology |
J:103063,
J:104171,
J:111488
|
|
abnormal myocardial fiber physiology |
J:104171
|
|
abnormal oxygen consumption |
J:22025,
J:22377
|
|
abnormal pain threshold |
J:152019
|
|
abnormal pancreatic beta cell physiology |
J:5400
|
|
abnormal protein level |
J:22025
|
|
abnormal skeletal muscle fiber type ratio |
J:151518
|
|
abnormal sleep pattern |
J:115771
|
|
abnormal sympathetic nervous system physiology |
J:145998
|
|
abnormal urine catecholamine level |
J:4033
|
|
abnormal urine homeostasis |
J:4033
|
|
allodynia |
J:152019
|
|
decreased body temperature |
J:129662
|
|
decreased cardiac muscle contractility |
J:104171,
J:111488
|
|
decreased circulating glucose level |
J:129554,
J:145998,
J:189019
|
|
decreased food intake |
J:29075
|
|
decreased insulin secretion |
J:145998
|
|
decreased locomotor activity |
J:115771,
J:122746
|
|
decreased NK cell number |
J:117826
|
|
decreased oxygen consumption |
J:22377
|
|
decreased skeletal muscle fiber size |
J:151518
|
|
decreased skeletal muscle mass |
J:151518
|
|
decreased white fat cell number |
J:22377
|
|
enlarged pancreatic islets |
J:5400
|
|
female infertility |
J:122746
|
|
fragmentation of sleep/wake states |
J:115771
|
|
heart left ventricle hypertrophy |
J:103063
|
|
hyperalgesia |
J:152019
|
|
hyperglycemia |
J:5400,
J:65486,
J:122746
|
|
hypoglycemia |
J:5400
|
|
impaired glucose tolerance |
J:104171,
J:107486
|
|
increased body weight |
J:185261
|
|
increased circulating cholesterol level |
J:18161
|
|
increased circulating HDL cholesterol level |
J:18161
|
|
increased circulating insulin level |
J:5400,
J:104171,
J:122746
|
|
increased circulating LDL cholesterol level |
J:18161
|
|
increased circulating triglyceride level |
J:18161,
J:104171
|
|
increased circulating VLDL cholesterol level |
J:18161
|
|
increased fat cell size |
J:189019
|
|
increased food intake |
J:129662
|
|
increased growth rate |
J:5400
|
|
increased insulin secretion |
J:145998
|
|
increased interscapular fat pad weight |
J:22377
|
|
increased metastatic potential |
J:117826
|
|
increased myocardial fiber size |
J:104171
|
|
increased oxygen consumption |
J:22377
|
|
increased percent body fat/body weight |
J:122746
|
|
insulin resistance |
J:104171
|
|
lung inflammation |
J:115772
|
|
obese |
J:103063,
J:104171
|
|
polyphagia |
J:122746
|
Lepob/Lepob
B6.Cg-Lepob/JBomTac
|
increased circulating triglyceride level |
J:149091
|
Lepob/Lepob
B6.Cg-Lepob/JRj
|
abnormal cell cycle |
J:220381
|
|
abnormal hepatocyte physiology |
J:220381
|
|
hepatic steatosis |
J:277927
|
|
normal
homeostasis/metabolism phenotype |
J:277927
|
|
increased body weight |
J:277927
|
|
increased cholesterol level |
J:277927
|
|
increased circulating free fatty acids level |
J:277927
|
|
increased hepatocyte apoptosis |
J:277927
|
|
increased susceptibility to diet-induced obesity |
J:277927
|
|
liver fibrosis |
J:277927
|
|
liver inflammation |
J:277927
|
|
macrovesicular hepatic steatosis |
J:277927
|
|
oxidative stress |
J:220381
|
Lepob/Lepob
B6.Cg-Lepob/OlaHsd
|
abnormal acute inflammation |
J:124815
|
|
abnormal chemokine secretion |
J:124815
|
|
abnormal digestive system physiology |
J:124815
|
|
abnormal intestinal epithelium morphology |
J:124815
|
|
increased interleukin-6 secretion |
J:124815
|
|
increased susceptibility to endotoxin shock |
J:124815
|
|
liver inflammation |
J:124815
|
Lepob/Lepob
BKS.Cg-Lepob/J
|
abnormal circulating cholesterol level |
J:18161
|
|
abnormal circulating glucose level |
J:5400
|
|
abnormal pancreatic beta cell physiology |
J:5400
|
|
hyperglycemia |
J:5400
|
|
increased circulating cholesterol level |
J:18161
|
|
increased circulating HDL cholesterol level |
J:18161
|
|
increased circulating insulin level |
J:5400
|
|
increased circulating LDL cholesterol level |
J:18161
|
|
increased circulating triglyceride level |
J:18161
|
|
increased circulating VLDL cholesterol level |
J:18161
|
|
increased growth rate |
J:5400
|
|
increased urine glucose level |
J:5400
|
|
polyuria |
J:5400
|
|
premature death |
J:5400
|
|
small pancreatic islets |
J:5400
|
Lepob/Lepob
BTBR.Cg-Lepob
|
hyperglycemia |
J:65486
|
Lepob/Lepob
BTBR.Cg-Lepob/WiscJ
|
abnormal pancreatic islet morphology |
J:106121
|
|
abnormal podocyte morphology |
J:185261
|
|
albuminuria |
J:185261
|
|
normal
cardiovascular system phenotype |
J:185261
|
|
decreased pancreatic beta cell mass |
J:106121
|
|
enlarged kidney |
J:185261
|
|
expanded mesangial matrix |
J:185261
|
|
glomerulosclerosis |
J:185261
|
|
hyperglycemia |
J:106121,
J:185261
|
|
hypotension |
J:185261
|
|
impaired glucose tolerance |
J:106121
|
|
increased blood urea nitrogen level |
J:185261
|
|
increased body weight |
J:185261
|
|
increased cholesterol level |
J:185261
|
|
increased circulating insulin level |
J:106121
|
|
increased circulating triglyceride level |
J:106121,
J:185261
|
|
increased kidney weight |
J:185261
|
|
increased renal glomerulus basement membrane thickness |
J:185261
|
|
insulin resistance |
J:106121
|
|
mesangiolysis |
J:185261
|
|
renal glomerulus hypertrophy |
J:185261
|
|
renal interstitial fibrosis |
J:185261
|
|
small pancreatic islets |
J:106121
|
Lepob/Lepob
D2.Cg-Lepob/Chua
|
abnormal pancreatic islet morphology |
J:78850
|
|
decreased pancreatic beta cell number |
J:78850
|
|
hyperglycemia |
J:78850
|
|
increased circulating insulin level |
J:78850
|
|
increased pancreatic beta cell number |
J:78850
|
|
obese |
J:78850
|
Lepob/Lepob
FVB.Cg-Lepob/Chua
|
hyperglycemia |
J:78850
|
|
increased circulating insulin level |
J:78850
|
Lepob/Lepob
involves: 129 * C57BL/6
|
abnormal lipid level |
J:121534
|
|
abnormal pancreatic islet morphology |
J:121534
|
|
decreased locomotor activity |
J:121534
|
|
enlarged pancreatic islets |
J:121534
|
|
hepatic steatosis |
J:121534
|
|
increased body weight |
J:121534
|
|
increased circulating insulin level |
J:121534
|
|
increased insulin secretion |
J:121534
|
|
increased pancreatic islet number |
J:121534
|
|
increased percent body fat/body weight |
J:121534
|
|
insulin resistance |
J:121534
|
|
polyphagia |
J:121534
|
Lepob/Lepob
involves: 129X1/SvJ * C57BL/6
|
abnormal adipose tissue amount |
J:107169
|
|
abnormal branching of the mammary ductal tree |
J:76479
|
|
abnormal circulating hormone level |
J:76479
|
|
abnormal circulating pancreatic peptide level |
J:76479
|
|
abnormal intestine morphology |
J:107169
|
|
abnormal vagina orifice morphology |
J:76479
|
|
absent corpus luteum |
J:76479
|
|
decreased circulating testosterone level |
J:76479,
J:107169
|
|
decreased lean body mass |
J:107169
|
|
decreased primary ovarian follicle number |
J:76479
|
|
decreased secondary ovarian follicle number |
J:76479
|
|
decreased seminal vesicle weight |
J:76479
|
|
decreased testis weight |
J:76479,
J:107169
|
|
female infertility |
J:76479
|
|
hyperglycemia |
J:107169
|
|
increased body weight |
J:107169
|
|
increased circulating cholesterol level |
J:107169
|
|
increased circulating corticosterone level |
J:76479,
J:107169
|
|
increased circulating insulin level |
J:76479,
J:107169
|
|
increased circulating leptin level |
J:76479
|
|
increased circulating triglyceride level |
J:107169
|
|
increased kidney weight |
J:107169
|
|
increased liver weight |
J:107169
|
|
increased pancreas weight |
J:107169
|
|
male infertility |
J:76479,
J:107169
|
|
polyphagia |
J:107169
|
|
prolonged diestrus |
J:76479
|
|
prolonged estrous cycle |
J:76479
|
|
prolonged estrus |
J:76479
|
Lepob/Lepob
involves: BTBR * C57BL/6 * V stock
|
decreased pancreatic beta cell number |
J:65486
|
|
disorganized pancreatic islets |
J:65486
|
|
hyperglycemia |
J:65486
|
|
increased circulating insulin level |
J:65486
|
|
pancreatic islet hyperplasia |
J:65486
|
Lepob/Lepob
involves: C57BL/6
|
decreased CD4-positive, alpha-beta T cell number |
J:164339
|
|
decreased splenocyte number |
J:164339
|
|
decreased T cell proliferation |
J:164339
|
|
increased circulating cholesterol level |
J:72027
|
|
increased circulating HDL cholesterol level |
J:72027
|
|
increased circulating triglyceride level |
J:72027
|
|
increased liver cholesterol level |
J:72027
|
|
increased liver triglyceride level |
J:72027
|
Lepob/Lepob
involves: C57BL/6J
|
abnormal behavior |
J:112820
|
|
abnormal cardiovascular system physiology |
J:116841
|
|
abnormal colon goblet cell morphology |
J:109110
|
|
abnormal corticosterone level |
J:13151
|
|
abnormal epidermal layer morphology |
J:121015
|
|
abnormal glucose homeostasis |
J:92558
|
|
abnormal hormone level |
J:13151
|
|
abnormal insulin secretion |
J:14402,
J:22634
|
|
abnormal intestinal mucosa morphology |
J:109110
|
|
abnormal muscle contractility |
J:106205
|
|
abnormal osteoclast differentiation |
J:60001
|
|
abnormal postnatal growth |
J:6236
|
|
abnormal respiratory electron transport chain |
J:116841
|
|
abnormal retina vasculature morphology |
J:92072
|
|
abnormal skeleton development |
J:60001
|
|
decreased locomotor activity |
J:219118
|
|
decreased nerve conduction velocity |
J:121015
|
|
enlarged pancreatic islets |
J:219118
|
|
hepatic steatosis |
J:219118
|
|
hyperglycemia |
J:92558,
J:219118
|
|
impaired glucose tolerance |
J:86303,
J:219118
|
|
increased adrenocorticotropin level |
J:13151
|
|
increased body length |
J:219118
|
|
increased bone mass |
J:60001
|
|
increased circulating corticosterone level |
J:60001
|
|
increased circulating insulin level |
J:92558
|
|
increased fasting circulating glucose level |
J:219118
|
|
increased fat cell size |
J:5765,
J:219118
|
|
increased gonadal fat pad weight |
J:219118
|
|
increased heart weight |
J:116841
|
|
increased inguinal fat pad weight |
J:219118
|
|
increased interscapular fat pad weight |
J:219118
|
|
increased lean body mass |
J:219118
|
|
increased liver weight |
J:219118
|
|
increased percent body fat/body weight |
J:219118
|
|
increased thermal nociceptive threshold |
J:121015
|
|
insulin resistance |
J:219118
|
|
obese |
J:92558,
J:219118
|
|
osteopetrosis |
J:60001
|
|
polyphagia |
J:219118
|
|
postnatal lethality, incomplete penetrance |
J:219118
|
Lepob/Lepob
involves: STOCK Mlphln a Tgfawa1 Cdh23v Ednrbs
|
abnormal arteriole morphology |
J:151096
|
|
abnormal cortical plate morphology |
J:105139
|
|
abnormal embryonic neuroepithelium morphology |
J:105139
|
|
abnormal fat cell morphology |
J:5253,
J:7702
|
|
abnormal gland physiology |
J:7702
|
|
abnormal glucose homeostasis |
J:7702
|
|
abnormal hormone level |
J:7702
|
|
abnormal long bone epiphyseal plate morphology |
J:102535
|
|
abnormal long bone epiphyseal plate proliferative zone |
J:102535
|
|
abnormal long bone hypertrophic chondrocyte zone |
J:102535
|
|
abnormal microglial cell physiology |
J:115569
|
|
abnormal nucleotide metabolism |
J:260830
|
|
abnormal pancreatic beta cell morphology |
J:7702
|
|
abnormal response to cardiac infarction |
J:219470
|
|
abnormal vascular wound healing |
J:135034
|
|
abnormal white adipose tissue morphology |
J:260830
|
|
decreased activity of thyroid gland |
J:7702
|
|
decreased body length |
J:13066
|
|
decreased body temperature |
J:12010
|
|
decreased bone mass |
J:7702
|
|
decreased circulating tumor necrosis factor level |
J:115569
|
|
decreased embryonic neuroepithelial cell proliferation |
J:105139
|
|
decreased embryonic neuroepithelium thickness |
J:105139
|
|
decreased length of long bones |
J:102535
|
|
decreased liver triglyceride level |
J:199803
|
|
decreased susceptibility to hepatic steatosis |
J:199803
|
|
female infertility |
J:7702
|
|
hyperglycemia |
J:7702
|
|
hypersecretion of corticosterone |
J:7702
|
|
impaired adaptive thermogenesis |
J:7702,
J:12010
|
|
impaired glucose tolerance |
J:7702
|
|
increased adrenocorticotropin level |
J:7702
|
|
increased body weight |
J:159285
|
|
increased circulating insulin level |
J:7702
|
|
increased fat cell size |
J:7702
|
|
increased growth rate |
J:13066
|
|
increased liver triglyceride level |
J:199803
|
|
increased pancreatic beta cell mass |
J:7702
|
|
increased pancreatic beta cell number |
J:7702
|
|
infertility |
J:7702
|
|
male infertility |
J:7702
|
|
polyphagia |
J:7702
|
|
reduced male fertility |
J:7702
|
|
short femur |
J:102535
|
|
short humerus |
J:102535
|
Lepob/Lepob
Tg(Npy-MAPT/Sapphire)1Rck/0
involves: C57BL/6 * CBA
|
abnormal excitatory postsynaptic currents |
J:90242
|
|
abnormal neuron morphology |
J:90242
|
|
decreased body weight |
J:90242
|
|
decreased food intake |
J:90242
|
|
increased food intake |
J:90242
|
|
normal
nervous system phenotype |
J:90242
|
Lepob/Lepob
Tg(Pomc-MAPT/Topaz)1Rck/0
involves: C57BL/6 * CBA
|
abnormal inhibitory postsynaptic currents |
J:90242
|
|
abnormal neuron morphology |
J:90242
|
|
decreased body weight |
J:90242
|
|
decreased food intake |
J:90242
|
|
increased food intake |
J:90242
|
Leptm1.1Gvcao/Leptm1.1Gvcao
Tg(Adipoq-cre)1Evdr/0
involves: 129S4/SvJaeSor * C57BL/6J * FVB/NTac
|
decreased circulating follicle stimulating hormone level |
J:218720
|
|
decreased circulating growth hormone level |
J:218720
|
|
decreased circulating leptin level |
J:218720
|
|
decreased circulating luteinizing hormone level |
J:218720
|
|
decreased circulating prolactin level |
J:218720
|
|
normal
endocrine/exocrine gland phenotype |
J:218720
|
|
female infertility |
J:218720
|
|
increased pituitary hormone level |
J:218720
|
|
infertility |
J:218720
|
|
male infertility |
J:218720
|
|
obese |
J:218720
|
Leptm1.2Gvcao/Leptm1.2Gvcao
involves: 129S4/SvJaeSor * FVB/NJ * FVB/NTac
|
decreased circulating follicle stimulating hormone level |
J:218720
|
|
decreased circulating leptin level |
J:218720
|
|
decreased circulating prolactin level |
J:218720
|
|
decreased pituitary hormone level |
J:218720
|
|
decreased somatotroph cell number |
J:218720
|
|
female infertility |
J:218720
|
|
increased body weight |
J:218720
|
|
infertility |
J:218720
|
|
male infertility |
J:218720
|
|
obese |
J:218720
|
Leptm1b(EUCOMM)Hmgu/Leptm1b(EUCOMM)Hmgu
C57BL/6N-Leptm1b(EUCOMM)Hmgu/Bay
|
abnormal coat appearance |
J:211773
|
|
abnormal eye posterior chamber depth |
J:211773
|
|
abnormal retina inner nuclear layer morphology |
J:211773
|
|
decreased exploration in new environment |
J:211773
|
|
decreased grip strength |
J:211773
|
|
decreased heart rate |
J:211773
|
|
decreased heart weight |
J:211773
|
|
decreased locomotor activity |
J:211773
|
|
decreased spleen weight |
J:211773
|
|
decreased total retina thickness |
J:211773
|
|
decreased vertical activity |
J:211773
|
|
female infertility |
J:211773
|
|
increased anxiety-related response |
J:211773
|
|
increased cardiac stroke volume |
J:211773
|
|
increased cornea thickness |
J:211773
|
|
male infertility |
J:211773
|
|
prolonged QRS complex duration |
J:211773
|
|
short tibia |
J:211773
|
Leptm1Kry/Leptm1Kry
Not Specified
|
increased bone mass |
J:88655
|
|
obese |
J:88655
|
Tg(Apcs-Lep)1Yog/0
involves: C57BL/6 * DBA/2
|
abnormal food intake |
J:57075
|
|
abnormal glucose homeostasis |
J:57075
|
|
abnormal lipid level |
J:57075
|
|
decreased body weight |
J:57075
|
|
decreased brown adipose tissue amount |
J:57075
|
|
decreased circulating insulin level |
J:57075
|
|
decreased circulating triglyceride level |
J:57075
|
|
decreased liver glycogen level |
J:57075
|
|
decreased liver triglyceride level |
J:57075
|
|
decreased liver weight |
J:57075
|
|
decreased white adipose tissue amount |
J:57075
|
|
increased insulin sensitivity |
J:57075
|
|
small pancreatic islets |
J:57075
|
Tg(Apcs-Lep)1Yog/?
involves: C57BL/6 * DBA/2
|
retina neovascularization |
J:92072
|
Tg(Apcs-Lep)1Yog/0
involves: C57BL/6J * FVB/N
|
abnormal food intake |
J:69591
|
|
abnormal glucose homeostasis |
J:69591
|
|
abnormal lipid level |
J:69591
|
|
decreased body weight |
J:69591
|
|
decreased brown adipose tissue amount |
J:69591
|
|
decreased circulating free fatty acids level |
J:69591
|
|
decreased circulating glucose level |
J:69591
|
|
decreased circulating insulin level |
J:69591
|
|
decreased circulating triglyceride level |
J:69591
|
|
decreased white adipose tissue amount |
J:69591
|
|
increased insulin sensitivity |
J:69591
|
|
small liver |
J:69591
|
|
small pancreatic islets |
J:69591
|
Tg(Apcs-Lep)1Yog/0
Not Specified
|
decreased bone mass |
J:88655
|
Tg(Apoe-Lep)1Kry/0
involves: FVB
|
abnormal bone ossification |
J:88655
|
|
abnormal food intake |
J:88655
|
|
decreased bone mass |
J:88655
|
|
decreased total body fat amount |
J:88655
|
Excel File
Analysis Tools